Tytuł artykułu

Vitamin D status and its associations with clinical and laboratory parameters in patients with Addison’s disease

Tytuł czasopisma

Folia Medica Cracoviensia




Vol. 61


No 2


Zawadzka, Karolina : Students’ Scientific Group of Endocrinology at the Department of Endocrinology, Jagiellonian University Medical College, Kraków, Poland ; Matwiej, Katarzyna : Students’ Scientific Group of Endocrinology at the Department of Endocrinology, Jagiellonian University Medical College, Kraków, Poland ; Sokołowski, Grzegorz : Chair and Department of Endocrinology, Jagiellonian University Medical College, Kraków, Poland ; Trofimiuk-Müldner, Małgorzata : Chair and Department of Endocrinology, Jagiellonian University Medical College, Kraków, Poland ; Skalniak, Anna : Chair and Department of Endocrinology, Jagiellonian University Medical College, Kraków, Poland ; Hubalewska-Dydejczyk, Alicja : Chair and Department of Endocrinology, Jagiellonian University Medical College, Kraków, Poland


Słowa kluczowe

primary adrenal insufficiency ; Addison’s disease ; vitamin D ; autoimmunity

Wydział PAN

Nauki Medyczne




Oddział PAN w Krakowie; Uniwersytet Jagielloński – Collegium Medicum


1. Adorini L., Penna G.: Control of autoimmune diseases by the vitamin D endocrine system. Nat Clin Pract Rheumatol. 2008; 4: 404–412.
2. Pilz S., Tomaschitz A., Obermayer-Pietsch B., Dobnig H., Pieber T.R.: Epidemiology of vitamin D insufficiency and cancer mortality. Anticancer Res. 2009; 29: 3699–4704.
3. Pilz S., März W., Wellnitz B., et al.: Association of Vitamin D Deficiency with Heart Failure and Sudden Cardiac Death in a Large Cross-Sectional Study of Patients Referred for Coronary Angiography. J Clin Endocrinol Metab. 2008; 93: 3927–3935.
4. Shapira Y., Agmon-Levin N., Shoenfeld Y.: Mycobacterium tuberculosis, autoimmunity, and vitamin D. Clin Rev Allergy Immunol. 2010; 38: 169–177.
5. Maruotti N., Cantatore F.P.: Vitamin D and the Immune System. J Rheumatol. 2010; 37: 491–495.
6. Kamen D.L., Aranow C.: The Link Between Vitamin D Deficiency and Systemic Lupus Erythema-tosus. Curr Rheumatol Rep. 2008; 10: 273–280.
7. Cutolo M.: Vitamin D and autoimmune rheumatic diseases. Rheumatology. 2009; 48: 210–212.
8. Hyppönen E.: Vitamin D and increasing incidence of type 1 diabetes — evidence for an association? Diabetes Obes Metab. 2010; 12: 737–743.
9. Ruiz-Irastorza G., Gordo S., Olivares N., Egurbide MV., Aguirre C.: Changes in vitamin D levels in patients with systemic lupus erythematosus: Effects on fatigue, disease activity, and damage. Arthritis Care and Res. 2010; 62: 1160–1165.
10. Munger K.L., Zhang S.M., O’Reilly E., et al.: Vitamin D intake and incidence of multiple sclerosis. Neurology. 2004; 62: 60–65.
11. Vaidya B., Chakera A.J., Dick C.: Addison’s disease. BMJ (Clinical research ed). 2009; 339:b2385.
12. Barthel A., Benker G., Berens K., et al.: An Update on Addison’s Disease. Exp Clin Endocrinol Diabetes. 2019; 127: 165–170.
13. Jeffery L.E., Burke F., Mura M., et al.: 1,25-Dihydroxyvitamin D 3 and IL-2 Combine to Inhibit T Cell Production of Inflammatory Cytokines and Promote Development of Regulatory T Cells Expressing CTLA-4 and FoxP3. J Immunol. 2009; 183: 5458–5467.
14. Prietl B., Treiber G., Pieber T.R., Amrein K.: Vitamin D and immune function. Nutrients. 2013; 5: 2502–2521.
15. Holick M.F., Binkley N.C., Bischoff-Ferrari H.A., et al.: Evaluation, treatment, and prevention of vitamin D deficiency: An endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011; 96: 1911–1930.
16. Chaudhary S., Dutta D., Kumar M., et al.: Vitamin D supplementation reduces thyroid peroxidase antibody levels in patients with autoimmune thyroid disease: An open-labeled randomized controlled trial. Indian J Endocrinol Metab. 2016; 20: 391–398.
17. Hyppönen E., Läärä E., Reunanen A., Järvelin M.R., Virtanen S.M.: Intake of vitamin D and risk of type 1 diabetes: A birth-cohort study. Lancet. 2001; 358: 1500–1503.
18. Munger K.L., Levin L.I., Hollis B.W., Howard N.S., Ascherio A.: Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA. 2006; 296: 2832–2838.
19. Lee Y.H., Bae S.C.: Vitamin D level in rheumatoid arthritis and its correlation with the disease activity: A meta-analysis. Clin Exp Rheumatol. 2016; 34: 827–833.
20. Zella J.B., McCary L.C., DeLuca H.F.: Oral administration of 1,25-dihydroxyvitamin D3 completely protects NOD mice from insulin-dependent diabetes mellitus. Arch Biochem Biophys. 2003; 417: 77–80.
21. Chen W., Lin H., Wang M.: Immune intervention effects on the induction of experimental autoimmune thyroiditis. J Huazhong Univ Sci Technolog Med Sci. 2002; 22: 343–345, 354.
22. Erichsen M.M., Løvås K., Skinningsrud B., et al.: Immune intervention effects on the induction of experimental autoimmune thyroiditis. Clinical, immunological, and genetic features of autoimmune primary adrenal insufficiency: observations from a Norwegian registry. J Clin Endocrinol Metab. 2009; 94: 4882–4890.
23. Betterle C., Dal Pra C., Mantero F., Zanchetta R.: Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: Autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction. Endocr Rev. 2002; 23: 327–364.
24. Yu L., Brewer K.W., Gates S., et al.: DRB1*04 and DQ alleles: expression of 21-hydroxylase autoantibodies and risk of progression to Addison’s disease. J Clin Endocrinol Metab. 1999; 84: 328–335.
25. Baker P.R., Baschal E.E., Fain P.R., et al.: Haplotype analysis discriminates genetic risk for DR3-associated endocrine autoimmunity and helps define extreme risk for Addison’s disease. J Clin Endocrinol Metab. 2010; 95: E263–70.
26. Mitchell A.L., Pearce S.H.S.: Autoimmune Addison disease: pathophysiology and genetic complexity. Nat Rev Endocrinol. 2012; 8: 306–316. 27. Aranow C.: Vitamin D and the immune system. J Investig Med. 2011; 59: 881–886.
28. Penna-Martinez M., Filmann N., Bogdanou D., et al.: High-dose vitamin D in Addison’s disease regulates T-cells and monocytes: A pilot trial. Nutrition (Burbank, Los Angeles County, Calif). 2018; 49: 66–73.
29. Pani M.A., Seissler J., Badenhoop K.: Vitamin D receptor genotype is associated with Addison’s disease. Eur J Endocrinol. 2002; 147: 635–640.
30. Demir K., Kattan W.E., Zou M., et al.: Novel CYP27B1 gene mutations in patients with vitamin D-dependent rickets type 1A. PLoS ONE. 2015; 10: e0131376.
31. Fichna M., Żurawek M., Januszkiewicz-Lewandowska D., et al.: Association of the CYP27B1 C(- 1260) A polymorphism with autoimmune Addison’s disease. Exp Clin Endocrinol Diabetes. 2010; 118: 544–549.
32. Jennings C.E., Owen C.J., Wilson V., Pearce S.H.S.: A haplotype of the CYP27B1 promoter is associated with autoimmune Addison’s disease but not with Graves’ disease in a UK population. J Mol Endocrinol. 2005; 34: 859–863.
33. Bellastella G., Maiorino M.I., Petrizzo M., et al.: Vitamin D and autoimmunity: what happens in autoimmune polyendocrine syndromes? J Endocrinol Invest. 2015; 38: 629–633.
34. Harms L.R., Burne T.H.J., Eyles D.W., McGrath J.J.: Vitamin D and the brain. Best Pract Res Clin Endocrinol Metab. 2011; 25: 657–669.
35. Cui X., Pelekanos M., Liu P.Y., Burne T.H.J., McGrath J.J., Eyles D.W.: The vitamin D receptor in dopamine neurons; its presence in human substantia nigra and its ontogenesis in rat midbrain. Neuroscience. 2013; 236: 77–87.
36. Meeusen R., Watson P., Hasegawa H., Roelands B., Piacentini M.F.: Central fatigue: The serotonin hypothesis and beyond. Sports Med. 2006; 36: 881–909.
37. Kaneko I., Sabir M.S., Dussik C.M., et al.: 1,25-DihydroxyVitamin D regulates expression of the tryptophan hydroxylase 2 and leptin genes: Implication for behavioral influences of Vitamin D. FASEB J. 2015; 29: 4023–4035.
38. Sinha A., Hollingsworth K.G., Ball S., Cheetham T.: Improving the vitamin D status of vitamin D deficient adults is associated with improved mitochondrial oxidative function in skeletal muscle. J Clin Endocrinol Metab. 2013; 98: E509–E513.
39. Ryan Z.C., Craig T.A., Folmes C.D., et al.: 1α,25-dihydroxyvitamin D3 regulates mitochondrial oxygen consumption and dynamics in human skeletal muscle cells. J Biol Chem. 2016; 291: 1514–1528.
40. Tomlinson P.B., Joseph C., Angioi M.: Effects of vitamin D supplementation on upper and lower body muscle strength levels in healthy individuals. A systematic review with meta-analysis. J Sci Med Sport. 2015; 18: 575–580.
41. Kamen D.L., Oates J.: A pilot randomized, controlled trial of vitamin D repletion to determine if endothelial function improves in patients with systemic lupus erythematosus. Am J Med Sci. 2015; 350: 302–307.
42. Lima G.L., Paupitz J., Aikawa N.E., Takayama L., Bonfa E., Pereira R.M.R.: Vitamin D Supplemen-tation in Adolescents and Young Adults with Juvenile Systemic Lupus Erythematosus for Improvement in Disease Activity and Fatigue Scores: A Randomized, Double-Blind, Placebo- Controlled Trial. Arthritis Care Res. 2016; 68: 91–98.
43. Beckmann Y., Türe S., Duman S.U.: Vitamin D deficiency and its association with fatigue and quality of life in multiple sclerosis patients. EPMA Journal. 2020; 11: 65–72.
44. Nowak A., Boesch L., Andres E., et al.: Effect of vitamin D3 on self-perceived fatigue A double-blind randomized placebo-controlled trial. Medicine. 2016; 95: 1–6.
45. van der Valk E.S., Smans L.C., Hofstetter H., et al.: Decreased physical activity, reduced QoL and presence of debilitating fatigue in patients with Addison’s disease. Clin Endocrinol (Oxf). 2016; 85: 354–360.
46. Bleicken B., Hahner S., Loeffler M., et al.: Influence of hydrocortisone dosage scheme on health-related quality of life in patients with adrenal insufficiency. Clin Endocrinol (Oxf). 2010; 72: 297–304.
47. Riedel M., Wiese A., Schürmeyer T.H., Brabant G.: Quality of life in patients with Addison’s disease: effects of different cortisol replacement modes. Exp Clin Endocrinol. 1993; 101: 106–111.
48. Bergthorsdottir R., Leonsson-Zachrisson M., Odén A., Johannsson G.: Premature Mortality in Patients with Addison’s Disease: A Population-Based Study. J Clin Endocrinol Metab. 2006; 91: 4849–4853.
49. Hahner S., Loeffler M., Fassnacht M., et al.: Impaired Subjective Health Status in 256 Patients with Adrenal Insufficiency on Standard Therapy Based on Cross-Sectional Analysis. J Clin Endocrinol Metab. 2007; 92: 3912–3922.
50. Laureti S., Vecchi L., Santeusanio F., Falorni A.: Is the prevalence of Addison’s disease under-estimated? J Clin Endocrinol Metab. 1999; 84: 1762.
51. Løvås K., Husebye E.S.: High prevalence and increasing incidence of Addison’s disease in western Norway. Clin Endocrinol (Oxf). 2002; 56: 787–791.
52. Jordan B., Uer O., Buchholz T., Spens A., Zierz S.: Physical fatigability and muscle pain in patients with Hashimoto thyroiditis. J Neurol. 2021 Jan 28. doi: 10.1007/s00415-020-10394-5.






DOI: 10.24425/fmc.2021.137224 ; ISSN 0015-5616